RBC Capital has been hearing investor questions on Edgewise Therapeutics (EWTX), which the firm believes may have been due to an FDA warning letter directed to a doctor who is an investigator associated with some of the company’s trials. However, weakness on read-throughs from a potential warning letter is “unwarranted” as the letter is not related to any conduct in any past or ongoing Edgewise studies, says the firm, which would “use the dip to accumulate shares” into the upcoming report of Phase 2 data. The firm maintains an Outperform rating and $44 price target on Edgewise.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise says FDA warning letter unrelated to any Edgewise clinical trial, data
- Edgewise moves off lows after stating FDA warning unrelated to company
- Edgewise should be bought on weakness as ARCH not likely FDA focus, says Truist
- Edgewise falls after FDA posts Warning Letter to trial investigator
- Edgewise Therapeutics price target raised to $50 from $33 at Truist